山东赛托生物科技股份有限公司 独立董事 2024 年度述职报告 本人作为山东赛托生物科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间，本人严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《公司章程》等相关法律法规的规定和要求履行独立董事的职务。现将本人2024 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 本人张启明，1961 年出生，中国国籍，无境外永久居留权，本科学历，毕业 于北京医科大学药学院。历任中国食品药品检定研究院化药室主任、药检处处长 等职务。第八至第十二届国家药典委员会委员，第十届和第十一届理化专业委员 会副主任委员，第十二届理化专业委员会第二专委会主任委员。《药物分析杂志》 《中国药事》《中国药品标准杂志》和《中国医药工业杂志》等多家专业杂志编 委。现任公司独立董事。 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独 立客观判断的关系，不存在影响独立董事独立性的情况。 二、独立董事年度履职概况 ...

山东赛托生物科技股份有限公司 独立董事 2024 年度述职报告 （一）出席董事会、股东大会情况 2024年度，本人任职期间公司共召开了5次董事会、1次股东大会。本人积极 参加公司召开的全部会议，没有缺席的情况。本人对董事会的各项议案均投出赞 成票，无异议的事项，也无反对、弃权的情形。出席会议具体情况如下： | | | 出席董事会情况 | | | 出席股东大会情况 | | --- | --- | --- | --- | --- | --- | | 应参加董 | 亲自出 | 委托出 | 缺席 | 是否连续两次 | 出席股东大会次数 | | 事会次数 | 席次数 | 席次数 | 次数 | 未出席会议 | | | 5 | 5 | 0 | 0 | 否 | 1 | 本人与公司经营管理层保持了充分沟通，了解公司经营情况，积极参与讨论 并提出合理建议，为公司董事会科学决策起到了积极作用。在董事会召开前，主 动了解并获取会议表决前所需要的背景情况和相关资料，认真审议会议议题，以 审慎的态度行使相应表决权。2024年公司董事会的召集、召开和表决均符合法定 程序，重大经营事项均履行了法定审批程序，合法有效。 本人作为山东赛托生物科 ...

Financial Performance - The company's revenue for Q1 2025 was ¥259,850,364.44, representing a 6.32% increase compared to ¥244,395,524.04 in the same period last year[5] - The net profit attributable to shareholders was -¥27,508,507.98, a significant decline of 995.83% from ¥3,070,728.65 in Q1 2024[5] - The basic and diluted earnings per share were both -¥0.15, down 850.00% from ¥0.02 in Q1 2024[5] - The net profit for the current period was a loss of ¥31,952,940.52, compared to a profit of ¥3,711,472.71 in the previous period, indicating a significant decline in profitability[21] - Total comprehensive income for the current period was a loss of ¥31,952,940.52, compared to a gain of ¥4,697,904.73 in the previous period[22] Cash Flow and Operating Activities - The cash flow from operating activities was -¥10,271,214.76, a decrease of 148.34% compared to ¥21,248,864.71 in the previous year[5] - The net cash flow from operating activities was a negative ¥10,271,214.76, a decline from a positive cash flow of ¥21,248,864.71 in the previous period[24] - The net cash flow from financing activities was ¥23,413,140.44, a decrease of 76.88% from ¥101,263,266.17 in the previous year[12] - Financing activities generated a net cash inflow of ¥23,413,140.44, down from ¥101,263,266.17 in the previous period, reflecting reduced borrowing activities[26] - The company’s investment activities resulted in a net cash outflow of ¥11,089,208.49, an improvement from a net outflow of ¥12,909,484.64 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,936,417,496.92, a decrease of 2.95% from ¥3,025,806,782.53 at the end of the previous year[5] - Total liabilities decreased from ¥1,141,641,832.99 to ¥1,084,205,487.90, a reduction of approximately 5.04%[18] - The company's total equity decreased from ¥1,884,164,949.54 to ¥1,852,212,009.02, a decline of about 1.69%[18] Operating Costs and Expenses - The company reported an increase in operating costs to ¥236,613,828.58, a rise of 35.35% from ¥174,821,291.66 in the same period last year[10] - Total operating costs increased to ¥285,808,740.98, up 19.8% from ¥238,473,780.69 in the previous period, primarily driven by a rise in operating costs which reached ¥236,613,828.58, up 35.4% from ¥174,821,291.66[20] - Research and development expenses were ¥10,449,182.96, down 26.5% from ¥14,321,901.84 in the previous period, reflecting a strategic focus on cost management[21] - Sales expenses decreased by 43.63% to ¥2,346,104.69 from ¥4,162,068.72 in Q1 2024[10] Shareholder Information - The total number of common shareholders at the end of the reporting period is 10,002[13] - The largest shareholder, Shandong Runxin Investment Co., Ltd., holds 22.82% of shares, totaling 43,297,382 shares[13] - The second-largest shareholder, Mi Chaojie, owns 20.62% of shares, amounting to 39,116,800 shares[13] Inventory and Receivables - Accounts receivable increased from ¥201,425,299.60 to ¥251,322,996.55, representing a growth of about 24.77%[16] - Inventory decreased from ¥644,877,938.66 to ¥550,279,833.26, a reduction of approximately 14.66%[17] - The company's cash and cash equivalents decreased from ¥255,962,580.48 to ¥229,945,988.16, a decline of approximately 10.16%[16] Future Outlook and Strategic Initiatives - Future outlook indicates a projected revenue growth of 25% for the next quarter, driven by new product launches[28] - Investment in R&D increased by 30%, focusing on innovative biotechnological solutions[28] - Market expansion plans include entering two new international markets by the end of 2025[28] - The company is exploring potential acquisitions to enhance its product portfolio and market presence[28] - New product line expected to contribute an additional 200 million RMB in revenue by Q3 2025[28] - Customer retention rate improved to 85%, reflecting enhanced user satisfaction[28] - The gross margin improved to 45%, up from 40% in the previous year[28] - Strategic partnerships with key industry players are being pursued to accelerate growth[28]

Financial Performance - The company's net profit attributable to shareholders decreased by 43.19 million RMB due to a decline in product prices and sales gross margin [6]. - The company recorded an impairment loss on inventory of 49.52 million RMB, impacting net profit attributable to shareholders [6]. - The company's operating revenue for 2024 is reported at ¥970,601,329.97, a decrease of 24.16% compared to ¥1,279,783,092.49 in 2023 [22]. - The net profit attributable to shareholders for 2024 is a loss of ¥88,766,731.73, representing a decline of 294.65% from a profit of ¥45,603,990.98 in 2023 [22]. - The basic earnings per share for 2024 is reported at -¥0.47, a decrease of 288.00% from ¥0.25 in 2023 [22]. - The net cash flow from operating activities increased by 309.44% to ¥194,459,589.28 in 2024, compared to ¥92,845,544.21 in 2023 [22]. - The net cash flow from operating activities for 2024 is projected to be 194.46 million RMB, significantly improved compared to the previous year [49]. - The company reported a net profit for the period at -¥101,328,265.58, primarily due to increased asset impairment losses [84]. - The cumulative distributable profit available to investors as of December 31, 2024, is RMB 278,696,334.13 [175]. Cash Flow and Investments - Operating cash flow significantly improved, with a positive net cash flow from operating activities, while period expenses slightly decreased compared to the previous year [6]. - The net cash flow from investment activities improved by 41.82%, resulting in a net outflow of ¥57,314,227.14 in 2024 [85]. - The net cash flow from financing activities decreased by 150.99%, leading to a net outflow of ¥163,036,731.74 [85]. - The company has invested nearly 400 million RMB in R&D since its establishment, with over 90 patents and software copyrights, including 25 invention patents [54]. - The total investment during the reporting period was ¥113,569,038.88, a 15.80% increase compared to ¥98,073,041.06 in the same period last year [94]. Business Strategy and Market Position - The company plans to enhance technology and optimize production processes in 2025 to further reduce product costs and improve quality and market competitiveness [6]. - The company emphasizes a "quality first, service foremost" business philosophy, achieving an increase in customer numbers and product sales despite price declines [6]. - The company aims to enhance its market competitiveness by implementing a full industry chain strategy encompassing intermediates, raw materials, and finished formulations [50]. - The company is focusing on maintaining cash flow stability and improving operational quality as its primary goal for 2024 [48]. - The company is committed to a strategy of "stabilizing market share, ensuring cash flow, promoting registrations, and divesting underperforming assets" in response to market challenges [57]. Research and Development - The company has established long-term partnerships with major pharmaceutical firms, leveraging its technological advantages in steroid drug raw materials [38]. - The company is exploring AI-driven innovative drug development in collaboration with AI biotechnology firms, aiming to extend its capabilities from intermediates to a full industry chain [41]. - The company’s R&D expenses for 2024 were ¥58,379,409.91, an increase of 6.00% compared to ¥55,076,380.87 in 2023 [80]. - The R&D expenditure as a percentage of operating income rose to 6.01% in 2024 from 4.30% in 2023 [82]. - The company has implemented a long-term development strategy for full-chain upgrades since 2019, with orderly execution over the past five years [134]. Environmental and Safety Management - The company has established a comprehensive safety and environmental management system, achieving zero major safety and environmental incidents in 2024 [60]. - The company strictly adheres to various environmental protection laws and regulations during its operations [183]. - The company has obtained pollution discharge permits and complies with discharge licensing systems [183]. - The company ensures that pollution control facilities operate stably and meet emission standards [183]. - Continuous investment in environmental protection has been made, with timely payment of environmental protection taxes as per regulations [192]. Governance and Compliance - The company maintained strict compliance with information disclosure regulations, ensuring transparency and timely communication with investors [144]. - The company has established a complete independent financial management system, with no shared bank accounts with controlling shareholders [146]. - The company possesses clear and independent ownership of all assets related to its operations, with no asset occupation by controlling shareholders [145]. - The company has a fully independent management structure, with no personnel decisions made outside the board of directors [146]. - The company has a dedicated investor relations strategy to enhance transparency and protect minority shareholders' rights [144]. Profit Distribution - The profit distribution plan proposes a cash dividend of 0.1 RMB per 10 shares, based on a total of 189,702,126 shares [10]. - The total amount of cash dividends distributed accounts for 0.68% of the total distributable profit [173]. - The company has not proposed any stock dividends or capital reserve transfers in the current profit distribution plan [176]. - The decision-making process for the profit distribution plan is complete and complies with the company's articles of association and shareholder meeting resolutions [173]. - The cash dividend distribution plan will be adjusted if there are changes in share capital due to stock incentives or convertible bonds before the implementation of the rights distribution [176].

山东赛托生物科技股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日 召开的第四届董事会第八次会议审议通过了《关于提请股东大会授权董事会以简 易程序向特定对象发行股票的议案》，董事会同意提请股东大会授权董事会以简 易程序向特定对象发行股票，募集资金总额不超过人民币 3 亿元且不超过最近一 年末净资产的 20%，授权期限自公司 2024 年年度股东大会审议通过之日起至公 司 2025 年年度股东大会召开之日止。上述事项尚需提交 2024 年年度股东大会审 议。具体情况如下： 证券代码：300583 证券简称：赛托生物 公告编号：2025-017 山东赛托生物科技股份有限公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导 性陈述或重大遗漏。 一、本次授权具体内容： 1、确认公司是否符合以简易程序向特定对象发行股票的条件 授权董事会根据相关法律、法规、规范性文件以及《公司章程》的规定，对 公司实际情况及相关事项进行自查论证，并确认公司是否符合以简易程序向特定 对象发行股票的条件。 2、发行证券的种类和数量 ...

证券代码：300583 证券简称：赛托生物 公告编号：2025-006 山东赛托生物科技股份有限公司 山东赛托生物科技股份有限公司 董 事 会 二〇二五年四月二十三日 关于归还闲置募集资金补充流动资金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"或"赛托生物"）于 2024 年 4 月 25 日召开第四届董事会第三次会议和第四届监事会第三次会议，审 议通过了《关于公司及全资子公司使用部分闲置募集资金暂时补充流动资金的议 案》，同意公司在保证募集资金投资项目建设资金需求的前提下，使用部分闲置 募集资金暂时补充流动资金，总额不超过人民币 20,000.00 万元，使用期限自董 事会审议批准之日起不超过十二个月，到期将归还至募集资金专户。具体内容详 见公司于 2024 年 4 月 29 日在巨潮资讯网上披露的《关于公司及全资子公司使用 部分闲置募集资金暂时补充流动资金的公告》（公告编号：2024-018）。 2025 年 4 月 23 日，公司将上述募集资金暂时补充流动资金全部归还至募集 资金专用账户，并将上述 ...

山东赛托生物科技股份有限公司 关于子公司收到化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司近日收到国家药品监督管理局签发的马来酸茚达特罗《化学原料药 上市申请批准通知书》，现将相关情况公告如下： 一、原料药登记信息 证券代码：300583 证券简称：赛托生物 编号：2025-005 化学原料药名称：马来酸茚达特罗/Indacaterol Maleate 包装规格：50g/桶，100g/桶，200g/桶，400g/桶，500g/桶，1.0kg/桶，2.0kg/ 桶 申请事项：境内生产化学原料药上市申请 生产企业：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 审评审批结果：A 二、原料药的相关情况 马来酸茚达特罗是一种长效β2-肾上腺素受体激动剂，吸入后其在肺内局部 发挥支气管扩张剂的作用，适 ...

本次会议由监事会主席张文霞女士主持，全体监事经认真审议并表决,会议 审议通过了以下议案： 审议通过《关于公司及子公司 2025 年度日常关联交易预计的议案》 经审核，全体监事一致认为：2025年度日常关联交易预计符合公司业务发展 的实际需求，交易定价合理、公允，严格遵循平等、自愿、公开、公平、公正的 原则，不存在损害公司和全体股东特别是中小股东利益的情形。不会影响公司的 独立性，也不会对公司持续经营能力产生影响。 表决结果：赞成3票，反对0票，弃权0票，获得通过。 证券代码：300583 证券简称：赛托生物 公告编号：2025-003 《关于公司及子公司 2025 年度日常关联交易预计的公告》的具体内容详见 公司信息披露网站巨潮资讯网（http://www.cninfo.com.cn）。 山东赛托生物科技股份有限公司监事会决议公告 特此公告。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）第四届监事会第七次 会议于2025年2月28日下午2:00在公司会议室召开，本次会议于2025年2月25日分 别以专人送达、 ...

证券代码：300583 证券简称：赛托生物 编号：2025-004 山东赛托生物科技股份有限公司 根据《深圳证券交易所创业板股票上市规则》《公司章程》等相关规定，上述议 案无需提交公司股东大会审议。 （二）预计 2025 年度日常关联交易类别和金额 | 关联交易 | 关联人 | 关联交易 | 关联交易定价 | 合同签订金额 或预计金额 | 截至披露日已发 | 上年发生金额 | | --- | --- | --- | --- | --- | --- | --- | | 类别 | | 内容 | 原则 | （万元） | 生金额（万元） | （万元） | | 销售商品及 | 信谊津津 | 产品 | 依照公允价格 | 8,200.00 | 953.94 | 4,051.82 | | 提供劳务 | | 小计 | | 8,200.00 | 953.94 | 4,051.82 | 注：上表数据均为不含税金额，且未经审计，最终关联交易金额以会计师审定的数据为准。 （三）上一年度日常关联交易实际发生情况 关于公司及子公司 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载 ...

国金证券股份有限公司 关于山东赛托生物科技股份有限公司及子公司 2025 年度日常关联交易预计的核查意见 国金证券股份有限公司（以下简称"保荐机构"）作为山东赛托生物科技股 份有限公司（以下简称"赛托生物"或"公司"）2022 年度以简易程序向特定对 象发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关规定，对赛托生物及子公司 2025 年度日常关 联交易预计事项进行了核查，核查情况及核查意见具体如下： 一、日常关联交易基本情况 （一）日常关联交易概述 山东赛托生物科技股份有限公司及子公司根据业务发展及日常经营需要，预 计2025年拟与关联方天津信谊津津药业有限公司（以下简称"信谊津津"）发生 日常关联交易，主要为向关联方销售商品及提供劳务等，预计2025年发生的日常 关联交易金额合计不超过8,200万元。2024年公司与前述关联方发生的日常关联 交易金额为4,051.82万元。 2025年2月28日，公司第四届董事会第七次会议以6票同意、0票反对、0票弃 权，审议通过了《关于公司及子 ...